Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Buy
61
CME Quote, Financials, Valuation and Earnings
Last price:
$277.88
Seasonality move
:
4.94%
Day range:
$276.37 - $279.87
52-week range:
$190.70 - $286.48
Dividend yield:
3.78%
P/E ratio:
27.96x
P/S ratio:
15.92x
P/B ratio:
3.71x
Volume:
1.6M
Avg. volume:
2.6M
1-year change:
30.4%
Market cap:
$100.2B
Revenue:
$6.1B
EPS (TTM):
$9.94
Analysts' Opinion
-
Consensus RatingCME Group has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $271.12, CME Group has an estimated downside of -2.46% from its current price of $277.94.
-
Price Target UpsideAccording to analysts, the highest upside price target is $305.00 representing -100% upside increase from its current price of $277.94.
Fair Value
-
According to the consensus of 11 analysts, CME Group has -2.46% downside to fair value with a price target of $271.12 per share.
CME vs. S&P 500
-
Over the past 5 trading days, CME Group has overperformed the S&P 500 by 1.54% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
CME Group does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
CME Group has grown year-over-year revenues for 15 quarters straight. In the most recent quarter CME Group reported revenues of $1.6B.
Earnings Growth
-
CME Group has grown year-over-year earnings for 4 quarters straight. In the most recent quarter CME Group reported earnings per share of $2.62.
Enterprise value:
102.1B
EV / Invested capital:
3.35x
Price / LTM sales:
15.92x
EV / EBIT:
21.11x
EV / Revenue:
16.24x
PEG ratio (5yr expected):
2.14x
EV / Free cash flow:
26.68x
Price / Operating cash flow:
26.16x
Enterprise value / EBITDA:
19.74x
Gross Profit (TTM):
$5.4B
Return On Assets:
2.63%
Net Income Margin (TTM):
57.71%
Return On Equity:
13.28%
Return On Invested Capital:
11.8%
Operating Margin:
67.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $5.1B | $5.6B | $6.3B | $1.5B | $1.6B | |
| Gross Profit | $4.3B | $4.8B | $5.4B | $1.3B | $1.4B | |
| Operating Income | $3.1B | $3.5B | $4.1B | $959.6M | $1.1B | |
| EBITDA | $4.3B | $4.6B | $5.2B | $1.2B | $1.4B | |
| Diluted EPS | $7.87 | $8.79 | $9.94 | $2.35 | $2.62 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $126.7B | $171B | $131B | $97.3B | $123.4B | |
| Total Assets | $160.7B | $205.9B | $166B | $132.1B | $157.8B | |
| Current Liabilities | $124.2B | $168.5B | $129B | $96.1B | $121.4B | |
| Total Liabilities | $134.1B | $178.2B | $138.7B | $104.9B | $130.8B | |
| Total Equity | $26.6B | $27.7B | $27.4B | $27.2B | $27B | |
| Total Debt | $3.4B | $3.4B | $3.4B | $3.4B | $3.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3.2B | $3.4B | $3.9B | $892.7M | $1.1B | |
| Cash From Investing | -$484.1M | $15.3M | -$75.8M | -$22.8M | -$16M | |
| Cash From Financing | -$42.8B | -$37.2B | $22.4B | $1.9B | $19.2B | |
| Free Cash Flow | $3.1B | $3.4B | $3.8B | $872.9M | $1.1B | |
CME
Sector
Market Cap
$100.2B
$628.1M
Price % of 52-Week High
97.02%
87.3%
Dividend Yield
3.78%
1.97%
Shareholder Yield
--
4.02%
1-Year Price Total Return
30.4%
9.14%
Beta (5-Year)
0.447
0.587
Dividend yield:
3.78%
Annualized payout:
$10.40
Payout ratio:
105.42%
Growth streak:
6 years
Technicals
8-day SMA
Buy
Level
$274.96
200-day SMA
Buy
Level
$236.98
Bollinger Bands (100)
Buy
Level
237.28 - 268.74
Chaikin Money Flow
Sell
Level
-6M
20-day SMA
Buy
Level
$274.08
Relative Strength Index (RSI14)
Buy
Level
57.54
ADX Line
Buy
Level
18.46
Williams %R
Neutral
Level
-41.1368
50-day SMA
Buy
Level
$266.28
MACD (12, 26)
Buy
Level
12.90
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
2.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.658)
Sell
CA Score
(Annual)
Level (-1.6701)
Buy
Beneish M-Score
(Annual)
Level (-2.4347)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (0.3929)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME’s acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
Stock Forecast FAQ
In the current month, CME has received 4 Buy ratings 7 Hold ratings, and 0 Sell ratings. The CME average analyst price target in the past 3 months is $271.12.
-
Where Will CME Group Stock Be In 1 Year?
According to analysts, the consensus estimate is that CME Group share price will drop to $271.12 per share over the next 12 months.
-
What Do Analysts Say About CME Group?
Analysts are divided on their view about CME Group share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that CME Group is a Sell and believe this share price will rise from its current level to $211.00.
-
What Is CME Group's Price Target?
The price target for CME Group over the next 1-year time period is forecast to be $271.12 according to 11 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is CME A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for CME Group is a Hold. 7 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CME?
You can purchase shares of CME Group via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase CME Group shares.
-
What Is The CME Group Share Price Today?
CME Group was last trading at $277.88 per share. This represents the most recent stock quote for CME Group. Yesterday, CME Group closed at $277.94 per share.
-
How To Buy CME Group Stock Online?
In order to purchase CME Group stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
99
SOC alert for May 20
Sable Offshore [SOC] is up 14.35% over the past day.
Buy
52
RGC alert for May 20
Regencell Bioscience Holdings [RGC] is down 10.93% over the past day.
Sell
40
GWLIF alert for May 20
Great-West Lifeco [GWLIF] is down 10.31% over the past day.
